Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Investor Presentation (January 2018)
21 slides from Precigen's investor presentation, Jan 8, 2018
Slide 1: ActoBio Therapeutics, Inc.
ActoBio Therapeutics™, Inc. Pieter Rottiers, PhD, Chief Executive Officer January 2018 Industriepark 7C Building D, 9052 Gent Belgium Tel: +32 9 277 11 77 | E-mail: IA.info@intrexon.com Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Some of the made in this pi ‘ion are forward-looki These forward- looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Aihough mana
Slide 3: ActoBio Therapeutics - Introduction
ActoBio Therapeutics™ - Introduction A new class of microbe-based biopharmaceuticals (ActoBiotics®) for expression and local delivery of therapeutics at disease sites For oral, gastrointestinal, and autoimmune/allergic disorders that are poorly served by current therapeutics Oral or topical administ
Slide 4: ActoBio Therapeutics - History
ActoBio Therapeutics™ - History Scientists at Flemish Institute for Biotechnology and University of Ghent began developing platform in 1995 ActoGeniX NV, a Belgian based company, was founded in 2006 to commercialize the scientists’ research that focused on ActoBiotics® for in situ expression / secre
Slide 5: ActoBio Therapeutics - Key Team Members
ActoBio Therapeutics™ - Key Team Members PIETER ROTTIERS, PhD Chief Executive Officer, Director Entrepreneurial leader with over 15 years experience in drug discovery and development using the ActoBiotics® platform, including over 13 years of leadership and managerial experience in biopharmaceutical
Slide 6: ActoBiotics - A Fully Integrated Microbial Drug Platform
ActoBiotics® - A Fully Integrated Microbial Drug Platform L. lactis essential gene removed Therapeutic gene inserted Construction strategy allows for minimum genetic modifications In-house established engineering process allows for continual creation of new drug candidates Host is engineered for env
Slide 7: Delivery of ActoBiotics Therapeutics
Delivery of ActoBiotics® Therapeutics 1 Genetically engineered bacterium freeze dried and inserted into enteric coated capsule 2 Capsule opens and releases the bacterium directly at the disease target 3 Bacterium releases the therapeutic protein locally at target site (e.g. in GI tract) ActoBiotics®
Slide 8: ActoBiotics Stand Out Compared to Existing Treatments
ActoBiotics® Stand Out Compared to Existing Treatments ActoBiotics® Low cost of goods a.o. because purification is not required Can be delivered orally in a capsule or in a topical solution No known toxicity or immunogenicity Targeted delivery; optimal tissue availability Simultaneous delivery of mu
Slide 9: Positive Effect of ActoBiotics Treatment on Colitis in Research Model
Positive Effect of ActoBiotics® Treatment on Colitis in Research Model Treatment daily for 2 or 4 weeks efficiently: (A) Cured colitis in chronic DSS model (B) Prevented onset of colitis in IL-10-/- mice With ActoBiotics® LLmIL10, a 10,000-fold lower dose was as effective as injected mIL10 Demonstra
Slide 10: ActoBiotics Active Delivery of Therapeutics at Site of Inflammation
ActoBiotics® Active Delivery of Therapeutics at Site of Inflammation Outcome of PK studies with oral L. lactis in mice with chronic colitis2 2Waeytens et al., 2007. Infl Bowel Dis.; Vandebroucke et al., 2010. Mucosal Immunol. L. lactis locates to the inflamed gut tissue as seen in confocal and elect
Slide 11: ActoBiotics Clinical and Development Pipeline
Oral Mucositis AG013 Phase 2 Oragenics Anti-TNF in PID (GI inflammation) AG014 Phase 1 - Inflammatory Bowel Disease (IBD) Multiple R&D - ActoBiotics® Clinical and Development Pipeline Gastrointestinal & Mucosal Autoimmune & Allergic Diseases Systemic Disorders Disease Type Type 1 Diabetes Multiple P
Slide 12: ActoBiotics Therapeutics in Autoimmune & Allergic Diseases
ActoBiotics® Therapeutics in Autoimmune & Allergic Diseases
Slide 13: Strategy Builds on Strong Research Foundation
Strategy Builds on Strong Research Foundation Takiishi et al. JCI 2012 Huibregtse et al. J. of Immunol. 2009
Slide 14: Unique Opportunities in Autoimmunity/Allergy
Unique Opportunities in Autoimmunity/Allergy Targeted mucosal delivery Superior efficacy vs. oral purified protein Co-delivery of multiple antigens/allergens Co-delivery of antigen/allergen with cytokines Reduction of local & systemic response Proof of concept established in autoimmune and allergic
Slide 15: Re-establish Tolerance in Autoimmunity with Oral ActoBiotics
Re-establish Tolerance in Autoimmunity with Oral ActoBiotics® ActoBiotics® antigen-specific immunotherapy is the first to harness all required elements – antigen, tolerance enhancing cytokine, and delivery – in a practical single therapeutic platform, ideally suited for efficient tolerance induction
Slide 16: Case study: ActoBiotics Therapeutics in Type 1 Diabetes
Case study: ActoBiotics® Therapeutics in Type 1 Diabetes (Joint Venture with Intrexon T1D Partners, LLC)
Slide 17: Overview of Type 1 Diabetes (T1D)
Overview of Type 1 Diabetes (T1D) Global Market Size/Epidemiology 2018 Addressable Population: apprx. 77,000 United States: 36,133 European Union: 40,046 Japan: 835 Target Patient Demographic Clinical recent-onset T1D patients Background Immune system destroys insulin-producing β-cells in the pancre
Slide 18: ActoBiotics Opportunity for Disease-modifying Treatment
ActoBiotics® Opportunity for Disease-modifying Treatment AG019 in T1D Value Proposition Current treatments do not re-establish long-term immunological tolerance to self-antigens Need for treatment to re-establish tolerance in order to maintain functional β-cell mass Ingested ActoBiotics® therapeutic
Slide 19: Superior Efficacy vs. Monotherapy in New Onset T1D
Superior Efficacy vs. Monotherapy in New Onset T1D AG019 (LL-[PINS] + IL-10) + anti-CD3 mAb most effective 60% of diabetic mice Reverted to normal blood sugar levels Preserved residual β-cell function Halted insulitis progression Treatment induced specific FoxP3+ Treg cells for long-term disease sup
Slide 20: ActoBiotics in T1D Summary and Outlook
ActoBiotics® in T1D Summary and Outlook Data Validation Proof-of-Concept and mechanism of action established in validated new-onset T1D animal model when combined with systemic low-dose anti-CD3 (2012) Progress to Date Non-clinical development plan and Phase 1b/2a clinical protocol reviewed during U
Slide 21: ActoBio Therapeutics Key Highlights
ActoBio Therapeutics™ Key Highlights ActoBiotics® technology is a fully integrated microbial drug delivery platform for biologicals with superior efficacy and safety potential through targeted delivery Therapeutic application across a broad set of markets with strong growth dynamics R&D engine creat